<DOC>
	<DOCNO>NCT02137837</DOCNO>
	<brief_summary>This randomized Phase III trial study well combination fulvestrant everolimus together combination anastrozole , fulvestrant everolimus together , improve progression-free survival ( PFS ) versus fulvestrant alone .</brief_summary>
	<brief_title>S1222 Trial ( Everolimus , Anastrozole Fulvestrant ) Post-Menopausal Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To test benefit interfere function estrogen receptor ( ER ) provide downstream target inhibition ( PI3K/AKT/mTOR ) combination optimal dose fulvestrant everolimus ( Arm 2 ) improve progression-free survival compare optimal dose fulvestrant alone ( Arm 1 ) . - To test benefit add non-steroidal aromatase inhibitor anastrozole optimal dose fulvestrant everolimus ( Arm 3 ) order improve progression free survival optimal dose fulvestrant ( Arm 1 ) . Secondary - To compare progression-free survival among receive fulvestrant + everolimus + anastrozole ( Arm 3 ) versus fulvestrant + everolimus ( Arm 2 ) . - To compare overall survival among treatment arm post-menopausal patient hormone-receptor positive ( HR+ ) Stage IV breast cancer . - To assess compare toxicity , feasibility compliance among study regimen . - To compare response rate clinical benefit rate among study regimen . - To test molecular determinant response endocrine therapy everolimus circulate tumor cell : 1 . CTC-Endocrine Therapy Index ( CTC ETI ) CellSearch® platform . 2 . CTC-Next Generation Sequencing Analysis ( CTC-NGS ) single cell capture HD-CTC® platform . OUTLINE : This multicenter study . Patients stratify accord follow factor : - Measurable versus evaluable non-measurable disease - Prior adjuvant hormonal therapy complete 5 year ago vs. prior adjuvant hormonal therapy complete 1-5 year ago vs. de novo presentation metastatic disease prior adjuvant hormonal therapy . ARMS : - Arm 1 : fulvestrant + placebo ( everolimus ) + placebo ( anastrozole ) - Arm 2 : fulvestrant + everolimus + placebo ( anastrozole ) - Arm 3 : fulvestrant + everolimus + anastrozole Blood tissue sample collect correlative science study . After completion study treatment , patient follow every 6 month 2 year yearly thereafter 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Patients must histologically confirm diagnosis invasive breast carcinoma positive estrogen and/or progesterone receptor status , negative human epidermal growth factor receptor ( HER2 ) , endocrine therapy plan . The HER2 test result negative ( report ) , single test ( test ) perform tumor specimen show : Immunohistochemistries ( IHC ) 1+ negative IHC 0 negative situ hybridization ( ISH ) negative use single probe ISH dual probe ISH . Estrogen receptor ( ER ) progesterone receptor ( PgR ) positivity must assess accord American Society Clinial Oncology ( ASCO ) /College American Physicians ( CAP ) guideline either ER PR ≥ 1 % positive nuclear staining . If HER2 IHC 2+ , evaluation gene amplification must perform gene must amplify . Gene amplification evaluation require evaluation IHC 0 1+ institutional standard . Patients must postmenopausal woman confirm diagnosis metastatic breast cancer ( M1 ) . Pathologic confirmation histology preferable . In case bone metastasis , biopsyproven metastatic disease solitary site , multiple site involvement require . Postmenopausal define one follow criterion per National Comprehensive Cancer Network ( NCCN ) guideline Version 3 . 2013 : Prior bilateral oophorectomy and/or hysterectomy Patients ≥ 60 year age Patients &lt; 60 year age amenorrheic ≥ 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression folliclestimulating hormone ( FSH ) estradiol postmenopausal range Patients &lt; 60 year age take tamoxifen toremifene must FSH plasma estradiol level within postmenopausal range Patients must measurable evaluable disease . Patients must chest abdominal computerize tomography ( CT ) bone scan within 28 day prior registration . All scan need assessment measurable disease must perform within 28 day prior registration . Evaluable disease must assess within 28 day prior registration Patients history prior chemotherapy hormone therapy immunotherapy recurrent metastatic disease NOT eligible . Prior adjuvant neoadjuvant chemotherapy complete 12 month prior registration acceptable . Any number prior hormonal therapy regimen adjuvant set metastatic recurrent disease allow ; prior adjuvant neoadjuvant treatment aromatase inhibitor ( e.g . anastrozole , letrozole , exemestane ) allow , complete 12 month prior randomization . Patients take luteinizing hormonereleasing hormone ( LHRH ) analogue adjuvant therapy eligible provide ) discontinue therapy least 12 month prior registration AND b ) resume menstrual period . Patients must prior exposure fulvestrant mTOR inhibitor ( e.g. , rapamycin , everolimus , temsirolimus , deforolimus ) . Concurrent bisphosphonate therapy allow . Patients must prior treatment investigational drug within 28 day prior registration must plan receive investigational drug duration study . Patients must International Normalized Ratio ( INR ) ≤ 1.6 within 28 day prior registration . Patients must adequate bone marrow function , define Absolute Neutrophil Count ( ANC ) ≥ 1,500/mL , hemoglobin ≥ 9 g/dL peripheral platelet count ≥ 100,000/ mL , within 28 day prior registration . Patients must adequate hepatic function obtain within 28 day prior registration document follow : Bilirubin ≤ 1.5 mg/dL ( ≤ 3.0 mg/dL due Gilbert 's Syndrome ) alanine aminotransferase ( ALT ) ( SGPT ) aspartate aminotransferase ( AST ) ( SGOT ) ≤ 2.5 x Institutional Upper Limit Normal ( IULN ) , ≤ 5 x IULN hepatic metastasis present . Patients must adequate renal function serum creatinine level ≤ IULN within 28 day prior registration . Patients must fast cholesterol ≤ 300 mg/dL triglyceride ≤ 2.5 x IULN obtain within 28 day prior registration . Patients may lipid lower agent reach value . Patients must complete history physical examination within 28 day prior registration . Patients bleed diathesis ( i.e. , disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) longterm anticoagulant therapy ( antiplatelet therapy ) NOT eligible . Patients presence lifethreatening metastatic visceral disease , define extensive hepatic involvement , degree brain leptomeningeal involvement ( past present ) , symptomatic pulmonary lymphangitic spread eligible . Patients discrete pulmonary parenchymal metastasis eligible , provided respiratory function significantly compromise result disease opinion investigator . Patients must performance status 0 2 Zubrod criterion . Patients must Grade III/IV cardiac disease define New York Heart Association Criteria ( i.e. , patient cardiac disease result marked limitation physical activity result inability carry physical activity without discomfort ) , unstable angina pectoris , myocardial infarction within 6 month , serious uncontrolled cardiac arrhythmia . Patients must uncontrolled diabetes ( define Hg A1C &gt; 7 % within 28 day prior registration ) . Patients must organ allograft history immune compromise . Patients must receive chronic , systemic treatment corticosteroid immunosuppressive agent . Topical inhale corticosteroid allow . Patients know HIV positive may enrol baseline CD4 count &gt; 500 cells/mm3 AND take antiretroviral therapy . Patients know chronic active hepatitis eligible . Patients must know uncontrolled underlying pulmonary disease . Patients must able take oral medication . Patient may impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . Patients must receive immunization attenuate live vaccine ( e.g . intranasal influenza , MMR , oral polio , varicella , zoster , yellow fever BCG vaccine ) within seven day prior registration plan receive vaccination protocol treatment . Patients must take within 14 day prior registration , take , plan take protocol treatment , strong CYP3A4 inhibitor , and/or CYP3A4 inducer . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer cancer patient diseasefree 5 year .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Invasive breast carcinoma</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>